RxDoctor Payments Data

Syed Hasan, MD

Neurology · Oregon, OHNPI 1215935846

Payments from drug & device makers

$2,992in general payments, 2019–2025

Across 194 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$581
  • AbbVie$512
  • EMD Serono, Inc.$240
  • Novartis$115
  • Teva Pharmaceuticals USA, Inc.$115
  • Acadia Pharmaceuticals Inc$91
  • plus $1K from 33 others

What the payments were for

  • Speaking & faculty fees$171%
  • Food & beverage$2,97599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,992 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$146,553
Medicare patients
495
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,452
Teriflunomide22$87,791
Aimovig AutoinjectorErenumab-Aooe26$34,298
Glatiramer Acetate13$20,241
Levetiracetam442$15,643
NeuproRotigotine13$11,076
Emgality PenGalcanezumab-Gnlm15$10,247
Lacosamide136$9,665
Carbamazepine ErCarbamazepine43$7,907
Rivastigmine28$7,048
Gabapentin249$6,334
Pyridostigmine Bromide33$4,166
Carbidopa-LevodopaCarbidopa/Levodopa161$3,760
Divalproex Sodium73$2,628
Oxcarbazepine38$2,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$59$97,45212 claims
UCB, Inc.Neupro$581$11,07613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.

Other neurology in Oregon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →